Tier 4 — mechanistic

Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial

Tan YJ, Zou TH, Yu K, Sheng JQ, Jin P, Zhang MJ, Zou XP, Dou XT, Liu SD, Huang SH, Ren JL, Yang XN, Liu ZJ, Sun XM, Wang BM, Cao HL, Zhang YX, Gao QY, Chen HM, Cui Y, Chen YX, Fang JY
Cell reports. Medicine 2025 6(9):102293

Bibliography

PubMed
PMID 40795846
PubMed Central
PMC12490254
DOI
10.1016/j.xcrm.2025.102293
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Indexed support: National Natural Science Foundation of China; Shanghai Shenkang Hospital Development Center; Shanghai Jiao Tong University; Innovative Research Team of High-level Local Universities in Shanghai; National Key Research and Development Program of China. See the publication for grant details.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignExtended post-trial observational follow-up
ModelHuman participants; see population
Sample781 re-enrolled; 648 had a follow-up colonoscopy
InterventionPost-treatment observational follow-up of NCT02226185
DurationUp to 6 years after original treatment
EndpointsPost-trial adenoma recurrence; Neoplasm occurrence; Follow-up colonoscopy ascertainment

What the study showed, in plain terms

Longer follow-up found lower adenoma recurrence among participants originally assigned berberine. Treatment had stopped, and follow-up was observational.

Key findings

  • Observed recurrence was 34.7% versus 52.1% among follow-up groups.

What this study can and cannot tell us

Shared cohort with PMID 31926918; selection, missing colonoscopies and post-trial exposures limit causal interpretation.

Related papers in the corpus

Tier 2
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study
Chen YX et al. · The lancet. Gastroenterology & hepatology · 2020
Tier 2
A Phase I Trial of Berberine in Chinese with Ulcerative Colitis
Xu L et al. · Cancer prevention research (Philadelphia, Pa.) · 2020
Tier 2
A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chen C et al. · Phytotherapy research : PTR · 2015
Tier 2
Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy
Li GH et al. · Medical oncology (Northwood, London, England) · 2010

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology